# A Novel Peritoneal Dialysis Fluid Based on Succinylated Gelatin and Citrate: A Preliminary Investigation of Efficacy, Safety, and Biocompatibility

**Authors:** Qing Xu, Zhifeng Zhou, Yi Zheng, Lu Jin, Chen Liu, Peiyun Li, Fang Wang, Ping Fu, Ling Zhang

PMC · DOI: 10.3390/ph19020222 · Pharmaceuticals · 2026-01-27

## TL;DR

A new peritoneal dialysis fluid using gelatin and citrate shows better biocompatibility and effectiveness compared to traditional glucose-based fluids, especially for short-term use.

## Contribution

The development and evaluation of a novel peritoneal dialysis fluid based on succinylated gelatin and citrate, offering improved biocompatibility and efficacy.

## Key findings

- The GEL-PDF showed a neutral pH and lower osmolality compared to glucose-based PDF.
- GEL-PDF provided effective short-term ultrafiltration and solute clearance, comparable to icodextrin-based PDF.
- Long-term use of GEL-PDF preserved peritoneal membrane structure and improved lipid profiles.

## Abstract

Introduction: The metabolic complications and poor biocompatibility of conventional glucose-based (GLU) peritoneal dialysis fluid (PDF) have driven the need for improved alternatives. To address this, we developed and evaluated a novel PDF utilizing succinylated gelatin (GEL) as osmotic agent and citrate as buffer, designed to provide effective solute clearance while offering enhanced biocompatibility. Methods: Physicochemical parameters (pH and osmolality) of the novel GEL-PDF were measured. Its performance was assessed in rats with chronic kidney disease. A total of 20 rats were randomized into short-term experiments to evaluate 4 h creatinine clearance and ultrafiltration (UF). A 12-week long-term experiment (n = 35) compared the GEL-PDF against normal saline (NS), GLU, and icodextrin-based (ICO) PDFs, monitoring survival, biochemical parameters, peritoneal membrane histology, and kidney histology. Results: The GEL-PDF demonstrated a neutral pH (7.30) and lower osmolality (317 mOsm/L) compared to GLU-PDF. In the short-term experiment, GEL-PDF achieved effective creatinine clearance by 4 h and provided higher 4 h UF than NS and GLU, comparable to ICO. However, during prolonged dwells (6–16 h), its UF was inferior to ICO. In the long-term experiment, GEL-PDF preserved peritoneal membrane structure, showing the least thickness and collagen deposition. Furthermore, the GEL-PDF demonstrated superior preservation of serum albumin compared to the GLU-PDF. It also exhibited a more favorable lipid profile, as evidenced by significantly lower total cholesterol levels than the ICO group at 12 weeks (p = 0.035), with no adverse effects on electrolytes, liver function, or glucose metabolism. Conclusions: The novel GEL and citrate-based PDF provide effective short-dwell UF and solute removal while exhibiting superior biocompatibility, as evidenced by significant protection against peritoneal membrane injury and favorable metabolic profiles. Although its long-duration UF was lower than that of ICO, it substantially outperformed GLU-PDF. These properties position the GEL-PDF as a promising candidate for short- to medium-dwell exchanges, particularly for daytime use, where it could fill an important clinical gap by providing enhanced UF without the high GLU exposure associated with conventional PDF.

## Linked entities

- **Chemicals:** citrate (PubChem CID 31348), glucose (PubChem CID 5793)
- **Diseases:** chronic kidney disease (MONDO:0005300)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Pdlim3 (PDZ and LIM domain 3) [NCBI Gene 114108] {aka Actn2lp, Alp}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, Got2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 25721] {aka ASPATA, mAAT}
- **Diseases:** dyslipidemia (MESH:D050171), fibrosis (MESH:D005355), inflammation (MESH:D007249), hypovolemic shock (MESH:D012769), injury (MESH:D014947), CKD (MESH:D051436), peritoneal fibrosis (MESH:D056627), tubular injury (MESH:D000230), peritoneal membrane failure (MESH:D051437), hypoalbuminemia (MESH:D034141), hemorrhage (MESH:D006470), burns (MESH:D002056), metabolic alkalosis (MESH:D000471), GEL (MESH:D011553), death (MESH:D003643), malnourished (MESH:D044342), hypocalcemia (MESH:D006996), metabolic acidosis (MESH:D000138), insulin resistance (MESH:D007333), toxicity (MESH:D064420), PD (MESH:D010538), gastrointestinal discomfort (MESH:D005767), ESKD (MESH:D007676), uremic (MESH:D006463), Liver Function (MESH:D056486), renal impairment (MESH:D007674), sepsis (MESH:D018805)
- **Chemicals:** P (MESH:D010758), Saline (MESH:D012965), paraffin (MESH:D010232), Gelofusine (MESH:D011097), magnesium chloride (MESH:D015636), TCA (MESH:D014233), nitrogen (MESH:D009584), Lac (MESH:D019344), isoflurane (MESH:D007530), chloride (MESH:D002712), cholesterol (MESH:D002784), Glu (MESH:D018698), adenine (MESH:D000225), calcium chloride (MESH:D002122), silicone (MESH:D012828), Hematoxylin (MESH:D006416), Na (MESH:D012964), K (MESH:D011188), sodium citrate (MESH:D000077559), H&amp;E (MESH:D006371), maltose (MESH:D008320), Ca2+ (-), HCO3- (MESH:D001639), Cl (MESH:D002713), Amino acid (MESH:D000596), Lipids (MESH:D008055), alkali (MESH:D000468), paraformaldehyde (MESH:C003043), Urea Nitrogen (MESH:C530477), Citrate (MESH:D019343), calcium (MESH:D002118), glucose (MESH:D005947), Cre (MESH:D003404), icodextrin (MESH:D000077607), Eosin (MESH:D004801)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942898/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942898/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942898/full.md

---
Source: https://tomesphere.com/paper/PMC12942898